TR199900191T2 - (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses. - Google Patents

(S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.

Info

Publication number
TR199900191T2
TR199900191T2 TR1999/00191T TR9900191T TR199900191T2 TR 199900191 T2 TR199900191 T2 TR 199900191T2 TR 1999/00191 T TR1999/00191 T TR 1999/00191T TR 9900191 T TR9900191 T TR 9900191T TR 199900191 T2 TR199900191 T2 TR 199900191T2
Authority
TR
Turkey
Prior art keywords
improved process
synthesis
dihydroxybutyric acid
esters
protected esters
Prior art date
Application number
TR1999/00191T
Other languages
English (en)
Turkish (tr)
Inventor
Elliott Jacks Thomas
Eugene Butler Donald
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of TR199900191T2 publication Critical patent/TR199900191T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/03Preparation of carboxylic acid esters by reacting an ester group with a hydroxy group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/32Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D317/34Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Furan Compounds (AREA)
  • Pyrane Compounds (AREA)
TR1999/00191T 1996-07-29 1997-07-01 (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses. TR199900191T2 (xx)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2236996P 1996-07-29 1996-07-29

Publications (1)

Publication Number Publication Date
TR199900191T2 true TR199900191T2 (xx) 1999-04-21

Family

ID=21809241

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/00191T TR199900191T2 (xx) 1996-07-29 1997-07-01 (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.

Country Status (17)

Country Link
US (1) US5998633A (enExample)
EP (1) EP0915866B1 (enExample)
JP (1) JP2000515882A (enExample)
KR (1) KR100447370B1 (enExample)
CN (1) CN1093126C (enExample)
AT (1) ATE215078T1 (enExample)
AU (1) AU3515497A (enExample)
CO (1) CO4950542A1 (enExample)
DE (1) DE69711391T2 (enExample)
DK (1) DK0915866T3 (enExample)
ES (1) ES2176756T3 (enExample)
HU (1) HU226465B1 (enExample)
IL (1) IL127058A (enExample)
PT (1) PT915866E (enExample)
TR (1) TR199900191T2 (enExample)
WO (1) WO1998004543A1 (enExample)
ZA (1) ZA976705B (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199900191T2 (xx) * 1996-07-29 1999-04-21 Warner-Lambert Company (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
ES2183587T3 (es) * 1998-07-24 2003-03-16 Samsung Fine Chemicals Co Ltd Procedimiento continuo para la preparacion de derivados de acido (s) -3-4-dihidroxibutirico opticamente puros..
US6713290B2 (en) 1998-07-24 2004-03-30 Samsung Fine Chemicals Co., Ltd. Process for preparing optically pure (S)-3-hydroxy-γ-butyrolactone
KR100332703B1 (ko) * 1998-07-24 2002-08-27 삼성정밀화학 주식회사 광학활성을갖는(s)-3,4-에폭시부티르산염의제조방법
US6235930B1 (en) * 1999-03-31 2001-05-22 Board Of Trustees Operating Michigan State University Process for the preparation of 3,4-dihydroxybutanoic acid and derivatives thereof from substituted pentose sugars
HU227840B1 (en) * 1999-05-06 2012-05-02 Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag Intermediates of atorvastatin synthesis and process for producing them
ES2258030T3 (es) 1999-12-17 2006-08-16 Pfizer Science And Technology Ireland Limited Procedimiento para producir atorvastatina calcio cristalina.
EP1584616A1 (en) 1999-12-17 2005-10-12 Pfizer Science and Technology Ireland Limited Industrial process for the production of crystalline atorvastatin trihydrate hemi calcium salt
JP4598917B2 (ja) * 2000-04-28 2010-12-15 ダイセル化学工業株式会社 ラクトンの製造方法
KR100645665B1 (ko) 2000-07-27 2006-11-13 에스케이 주식회사 (s)-베타-하이드록시-감마-부티로락톤의 연속 제조방법
US6476235B2 (en) 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
EP1734034A3 (en) 2001-01-09 2007-01-03 Warner-Lambert Company LLC Carboxylic acid salts of beta-alanine esters or -amides
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
BR0210666A (pt) 2001-06-29 2004-10-05 Warner Lambert Co Formas cristalinas do sal de cálcio do ácido [r-(r*,r*)]-2-(4-fluorofenil)-beta, delta-dihidróxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)c arbonil]-1h-pirrol-1-heptanóico (2:1) (atorvastatina)
MXPA03012045A (es) * 2001-07-06 2004-03-29 Teva Pharma Proceso para preparar derivados del acido 7-amino sin 3,5-dihidroxi heptanoico a traves de derivados del acido 6-ciano sin 3,5-dihidroxi hexanoico.
BR0215602A (pt) * 2002-02-25 2004-12-07 Biocon Ltd ésteres de boronato
GB0211716D0 (en) 2002-05-22 2002-07-03 Phoenix Chemicals Ltd Process
CN100357289C (zh) 2002-08-06 2007-12-26 沃尼尔·朗伯有限责任公司 制备5-(4-氟苯基)-1-[2-((2r,4r)-4-羟基-6-氧代-四氢-吡喃-2-基)乙基]-2-异丙基-4-苯基-1h-吡咯-3-羧酸苯基酰胺的方法
EP1558597B1 (en) * 2002-09-18 2008-05-07 SK Holdings Co., Ltd. Continuous process for the production of optically pure (s)-beta hydroxy-gamma-butyrolactone
AU2003263031A1 (en) * 2002-09-20 2004-04-08 Diversa Corporation Chemoenzymatic methods for the synthesis of statins and stain intermediates
US6713639B1 (en) 2002-10-28 2004-03-30 Council Of Scientific And Industrial Research Process for preparing enantiomerically pure (S)-3-hydroxy-gamma-butyrolactone
EP1615883A1 (en) * 2003-04-14 2006-01-18 Warner-Lambert Company Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
ES2323366T3 (es) * 2003-04-22 2009-07-14 Biocon Limited Procedimiento novedoso para la reduccion estereoselectiva de beta-cetoesteres.
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R-(R*,R*)]-2-(4-氟苯基)-β,δ-二羟基-5-(1-甲基乙基)-3-苯基-4-[(苯基氨基)羰基]-1H-吡咯-1-庚酸的结晶形式
WO2005068642A2 (en) 2003-10-01 2005-07-28 Board Of Trustees Operating Michigan State University Bacterial synthesis of 1,2,4-butanetriol enantiomers
CN1960972A (zh) * 2004-04-16 2007-05-09 辉瑞产品公司 用于形成无定形阿托伐它汀钙的方法
CA2649054A1 (en) 2004-05-05 2005-11-10 Pfizer Products Inc. Salt forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid
JP2008506764A (ja) 2004-07-20 2008-03-06 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー [R−(R*,R*)]−2−(4−フルオロフェニル)−β、δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸カルシウム塩(2:1)の新規形態
WO2006046109A1 (en) 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
DE602006013815D1 (de) * 2005-05-31 2010-06-02 Kowa Co Verfahren zur herstellung von optisch aktiven ppar-aktivierenden verbindungen und zwischenprodukte für die herstellung
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
ATE466840T1 (de) 2005-11-21 2010-05-15 Warner Lambert Co Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium
US20110165641A1 (en) * 2006-03-31 2011-07-07 The Board Of Trustees Of Michigan State University Synthesis of 1,2,4-Butanetriol Enantiomers from Carbohydrates
WO2008091288A2 (en) * 2006-07-19 2008-07-31 Board Of Trustees Of Michigan State University Microbial synthesis of d-1,2,4-butanetriol
KR100850558B1 (ko) 2008-01-02 2008-08-06 조동옥 아토르바스타틴의 효율적인 제조방법
JP2009256316A (ja) 2008-03-28 2009-11-05 Daicel Chem Ind Ltd β−ヒドロキシ−γ−ブチロラクトンの製造方法
CN101337906B (zh) * 2008-08-15 2012-06-27 河南豫辰精细化工有限公司 一种4-甲基-3-氧代-n-苯基戊酰胺的制备方法
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2373609B1 (en) 2008-12-19 2013-10-16 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US20140335179A1 (en) 2011-07-01 2014-11-13 Dsm Sinochem Pharmaceuticals Netherlands B.V. Micronized crystals of atorvastatin hemicalcium
CN106397241A (zh) * 2016-08-23 2017-02-15 杨锋 一种4‑甲基‑3‑氧代‑n‑苯基戊酰胺的绿色环保后处理方法
CN106588689A (zh) * 2016-12-15 2017-04-26 河南豫辰药业股份有限公司 一种从结晶母液废液中回收阿托伐他汀中间体m4的方法
CN112939901B (zh) * 2021-02-09 2023-05-09 中国科学院福建物质结构研究所 一种α-羟基-γ-丁内酯的制备方法
CN114195670B (zh) * 2021-12-31 2024-03-15 河南豫辰药业股份有限公司 一种阿托伐他汀母核m4的精制方法
CN117447350B (zh) * 2023-10-26 2026-02-13 河南豫辰药业股份有限公司 一种阿托伐他汀m4有机废物综合再利用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2710688B2 (ja) * 1990-10-09 1998-02-10 鐘淵化学工業株式会社 4―ブロモ―3―ヒドロキシ酪酸エステル誘導体の製造法
CA2049536C (en) * 1991-05-13 1999-07-06 Rawle I. Hollingsworth Process for the preparation of 3,4-dihydroxybutanoic acid and salts thereof
JP3351563B2 (ja) * 1992-12-03 2002-11-25 鐘淵化学工業株式会社 3−ヒドロキシ酪酸誘導体の製造法
TR199900191T2 (xx) * 1996-07-29 1999-04-21 Warner-Lambert Company (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.

Also Published As

Publication number Publication date
ZA976705B (en) 1998-02-10
HU226465B1 (en) 2008-12-29
KR20000029648A (ko) 2000-05-25
CN1093126C (zh) 2002-10-23
JP2000515882A (ja) 2000-11-28
HUP9904348A2 (hu) 2000-04-28
HK1020728A1 (en) 2000-05-19
DK0915866T3 (da) 2002-06-10
EP0915866A1 (en) 1999-05-19
CO4950542A1 (es) 2000-09-01
EP0915866B1 (en) 2002-03-27
IL127058A0 (en) 1999-09-22
US5998633A (en) 1999-12-07
ES2176756T3 (es) 2002-12-01
PT915866E (pt) 2002-07-31
HUP9904348A3 (en) 2004-03-01
ATE215078T1 (de) 2002-04-15
DE69711391D1 (de) 2002-05-02
CN1223647A (zh) 1999-07-21
IL127058A (en) 2001-07-24
DE69711391T2 (de) 2002-11-07
KR100447370B1 (ko) 2004-09-08
AU3515497A (en) 1998-02-20
WO1998004543A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
TR199900191T2 (xx) (S)-3,4-Dihidroksibutirik asitin korumal� esterlerinin sentezi i�in geli�tirilmi� proses.
NO975387L (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
RU95114376A (ru) Нитроэфиры, обладающие фармакологической активностью, и способ их получения
HUP0100845A3 (en) Hydroxamid acid derivatives as matrix metalloprotease(mmp) inhibitors, process for producing them and pharmaceutical compositions containing them
TR199600792A2 (tr) Dihaloazolopirimidinlerin hazirlanmasina yönelik proses.
ID19926A (id) Proses untuk produksi asam tereftalat murni
ID21654A (id) Proses derivatisasi selektif taksana
PL341054A1 (en) Novel suppositiories containing an active compound being unstable in acid environments
IT1226726B (it) Composti attivi come inibitori della biosintesi del colesterolo.
HUP9901079A3 (en) 5- and 6-membered cyclic compounds containing nitrogenatom, pharmaceutical compositions containing them, their use for producing pharmaceutical compositions and their producing
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
MX9800408A (es) Sales de derivados de amidina y de inhibidor de ciclooxigenasa, su procedimiento de preparacion, su aplicacion como medicamentos y composiciones farmaceuticas que los contienen.
AU6505299A (en) Methods for generating antigen-reactive t cells (in vitro)
HUP0002853A3 (en) 6,7-asymmetrically disubstituted quinoxalinecarboxylic acid derivatives, and pharmaceutical compositions containing them
NZ325235A (en) New phenylamidine derivatives, a process for preparing the same and their use as medicaments
ZA979756B (en) Substituted 4-biphenyl-4-hydroxybutyric acid derivatives as matrix metalloprotease inhibitors.
MXPA03010251A (es) Proceso para la preparacion de ribavirina.
JPS5433634A (en) Information read-in system
ID29219A (id) (1-fenasi-3-fenil-3-piperidiletil): turunan-turunan piperidin, proses untuk memperolehnya dan komposisi-komposisi farmasi
FI945328A7 (fi) Laitos sähköenergian tuottamiseksi polttoaineista, erityisesti biogeenisistä polttoaineista
ES542835A0 (es) Procedimiento de preparar un antigeno relacionado con el ligamento glicosidico,derivado de celulas de cancer.
CA2294158A1 (en) Natural antitumor or antiviral substances and use of the same
MY122830A (en) Process for the preparation of (alpha)-(2-4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof
PL353926A1 (en) Process for the preparation of 2-cyanopyridines
CA2298523A1 (en) Therapeutic process for inhibiting nf-.kappa.b